ATG-037 is Antengene's oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy
- The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy and in combination with KEYTRUDA® for the treatment of locally advanced or metastatic solid tumors- The study of ATG-037 monotherapy started enrolling patients in Q2 2022 and will include the combination with KEYTRUDA® in 2023
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.